Personal information

Emails & domains

Verified email addresses

Verified email domains

Websites & social links

Group Web Site
Group Twitter

Other IDs

ResearcherID: C-6148-2016
Loop profile: 175802
Scopus Author ID: 7102824561
Loop profile: 707489

Keywords

Metabolism, Cancer, Aging, Biocompounds, Cancer therapy, Immunometabolism, Biology systems, Autophagy, Senescence

Countries

Spain, United States

Activities

Collapse all

Employment (9)

Institut Català d'Oncologia Badalona: Girona, Catalunya, ES

2010-06 to present | Tenure (Group Leader, Program Against Cancer Therapeutic Resistance (ProCURE))
Employment
Source: Self-asserted source
Javier A. Menendez

Institut Català d'Oncologia Girona: Girona, Catalunya, ES

2007-06 to 2010-06 | Research Scientist (Translational Research Unit)
Employment
Source: Self-asserted source
Javier A. Menendez

Girona Biomedical Research Institute: Girona, ES

2006-01 to 2007-06 | “Miguel Servet” Research Scientist (Carlos III Institute of Health)
Employment
Source: Self-asserted source
Javier A. Menendez

Robert H Lurie Comprehensive Cancer Center: Chicago, IL, US

2005-02 to 2006-01 | Faculty Member
Employment
Source: Self-asserted source
Javier A. Menendez

Northwestern University Feinberg School of Medicine: Chicago, IL, US

2003-01 to 2006-01 | Assistant Professor
Employment
Source: Self-asserted source
Javier A. Menendez

Evanston Northwestern Healthcare: Evanston, Illinois, US

2004-09 to 2005-12 | Scientist
Employment
Source: Self-asserted source
Javier A. Menendez

Evanston Northwestern Healthcare: Evanston, Illinois, US

2002-06 to 2003-01 | Research Associate
Employment
Source: Self-asserted source
Javier A. Menendez

University of California Berkeley: Berkeley, CA, US

2001-10 to 2002-06 | Biologist Visiting Post-Doctoral Fellow (Lawrence Berkeley National Laboratory (LBNL))
Employment
Source: Self-asserted source
Javier A. Menendez

Hospital Universitario 12 de Octubre: Madrid, Comunidad de Madrid, ES

1997-10 to 2001-10 | Pre-Doctoral Fellow (Medical Oncology Department)
Employment
Source: Self-asserted source
Javier A. Menendez

Education and qualifications (3)

Facultad de Biología, Universidad Complutense de Madrid.: Madrid, ES

2001 | PhD in Biochemistry and Molecular Biology
Education
Source: Self-asserted source
Javier A. Menendez

Universidad Complutense de Madrid: Madrid, Comunidad de Madrid, ES

1997 to 2001 | Master of Science (Medical Oncology Department, University Hospital 12 de Octubre)
Education
Source: Self-asserted source
Javier A. Menendez

Universidad de Oviedo, Facultad de Biología: Oviedo, Asturias, ES

1997 | Bachelor’s Degree in Biological Sciences
Education
Source: Self-asserted source
Javier A. Menendez

Professional activities (18)

Ayuntamiento de Langreo: Langreo, Principado de Asturias, ES

Insignia de Oro del Ayuntamiento de Langreo. “Fatty acids for the treatment of human cancer”
Distinction
Source: Self-asserted source
Javier A. Menendez

Society for Translational Oncology: Durham, NC, US

2010 to present
Membership
Source: Self-asserted source
Javier A. Menendez

INTERNATIONAL DOSE-RESPONSE SOCIETY: Amherst, MA, US

2010 to present
Membership
Source: Self-asserted source
Javier A. Menendez

European Society for Clinical Investigation: Utrecht, NL

2009 to present
Membership
Source: Self-asserted source
Javier A. Menendez

European Association For Cancer Research: Nottingham, Nottingham, GB

2007 to present
Membership
Source: Self-asserted source
Javier A. Menendez

American Association For Cancer Research: Philadelphia, Pennsylvania, US

2001 to present
Membership
Source: Self-asserted source
Javier A. Menendez

Fujitsu (Japan): Minato, JP

2016 | FUJITSU-INNOMEDYX Award Best Innovative Healthcare Idea 2016
Distinction
Source: Self-asserted source
Javier A. Menendez

Institut d'Investigació Biomèdica de Girona Dr Josep Trueta: Girona, Catalunya, ES

2011 | Premio al Mejor Investigador Joven (< 40 años) del Instituto de Investigación
Distinction
Source: Self-asserted source
Javier A. Menendez

Caja Rural de Jaén: Jaen, Andalucía, ES

2011 | I Premio de Investigación sobre Aceite de Oliva y Salud.
Distinction
Source: Self-asserted source
Javier A. Menendez

"El Correo Farmacéutico": Madrid, ES

2008 | EL CORREO FARMACÉUTICO “BEST IDEAS AWARD of the YEAR 2007”. “Anti-diabetes drugs for the prevention and treatment of cancer”
Distinction
Source: Self-asserted source
Javier A. Menendez

Susan G. Komen Breast Cancer Foundation: Dallas, Texas, US

2006 | SUSAN G. KOMEN BREAST CANCER FOUNDATION AWARD on Basic, Clinical and Translational Research (EEUU)
Distinction
Source: Self-asserted source
Javier A. Menendez

ANNALS OF ONCOLOGY: Philadelphia, US

2006 | ANNALS OF ONCOLOGY PRIZE FOR BEST ARTICLE IN TRANSLATIONAL SCIENCE 2004-2006
Distinction
Source: Self-asserted source
Javier A. Menendez

Robert H Lurie Comprehensive Cancer Center: Chicago, IL, US

2005 | CAREER DEVELOPMENT AWARD.
Distinction
Source: Self-asserted source
Javier A. Menendez

"La Nueva España": Oviedo, Principado de Asturias, ES

2005 | Asturiano del mes (“La Nueva España”, Principado de Asturias, Spain). “Fatty acids for the treatment of human cancer”
Distinction
Source: Self-asserted source
Javier A. Menendez

"Diario Médico": Madrid, ES

2005 | DIARIO MEDICO’s “BEST IDEAS AWARD of the YEAR 2005”. Research and Pharmacology category; “Study on Olive oil and Breast Cancer”
Distinction
Source: Self-asserted source
Javier A. Menendez

Susan G. Komen Breast Cancer Foundation: Dallas, Texas, US

2004 | SUSAN G. KOMEN BREAST CANCER FOUNDATION AWARD on Basic, Clinical and Translational Research
Distinction
Source: Self-asserted source
Javier A. Menendez

National Cancer Institute: Bethesda, US

2004 | CAREER DEVELOPMENT AWARD. Specialized Program of Research Excellence –SPORE- in Breast Cancer. País entidad
Distinction
Source: Self-asserted source
Javier A. Menendez

Instituto Danone: Barcelona, Catalunya, ES

2001 | Awards on Food, Nutrition and Health
Distinction
Source: Self-asserted source
Javier A. Menendez

Funding (45)

Rethinking fatty acid synthase activity as an information–processing system for functional precision oncology (FASINPRE)

2023-10 to 2026-10 | Grant
Ministerio de Ciencia y Tecnología (Madrid, ES)
GRANT_NUMBER:

PID2022-141955OB-I00

Source: Self-asserted source
Javier A. Menendez

METABOLIC DEPENDENCES AND DIETARY REGULATION OF IMMUNE-CHECKPOINTS: NEW TARGETS FOR CANCER IMMUNOTHERAPY RESISTANCE

2020-06 to 2023-05 | Contract
programa: PLAN NACIONAL DE I+D+I. PROYECTOS DE INVESTIGACION FUNDAMENTAL NO-ORIENTADA (Madrid, ES)
GRANT_NUMBER:

PID2019-104055GB-I00
Source: Self-asserted source
Javier A. Menendez

A therapeutic strategy to co-target brain metastasis-initiating and hyperlipidemia-driving mechanisms in lorlatinib-treated NSCLC

2019 to 2021 | Contract
Pfizer Japan (Madrid, ES)
Source: Self-asserted source
Javier A. Menendez

A METABOLOMIC FRAMEWORK FOR REDUCING AND EXPLOITING THE MULTIDIMENSIONAL COMPLEXITY OF TUMOR HETEROGENEITY: SUB-PHENOTYPING OF CANCER STEM CELL METABOLOMIC STATES. SAF2016-80639

2016 to 2018 | Contract
Ministerio de Economía y Competitividad (Madrid, ES)
GRANT_NUMBER:

PLAN NACIONAL DE I+D+I. PROYECTOS DE INVESTIGACION FUNDAMENTAL NO-ORIENTADA. Convocatoria 2016. SAF2016-80639-P
Source: Self-asserted source
Javier A. Menendez

Contratos Postdoctorales de Perfeccionamiento en Investigación en Salud “Sara Borrell”. CD15/00033

2016 to 2018 | Contract
Instituto de Salud Carlos III (Madrid, ES)
GRANT_NUMBER:

Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Contratos Postdoctorales de Perfeccionamiento en Investigación en Salud “Sara Borrell”
Source: Self-asserted source
Javier A. Menendez

IMPACTO DEL METABOLISMO ENERGÉTICO EN LAS MODIFICACIONES EPIGENÉTICAS DERIVADAS DE LA COMBINACIÓN DE DIABETES Y OBESIDADIMPACTO DEL METABOLISMO ENERGÉTICO EN LAS MODIFICACIONES EPIGENÉTICAS DERIVADAS DE LA COMBINACIÓN DE DIABETES Y OBESIDADIMPACTO DEL METABOLISMO ENERGÉTICO EN LAS MODIFICACIONES EPIGENÉTICAS DERIVADAS DE LA COMBINACIÓN DE DIABETES Y OBESIDAD

2016 to 2018 | Contract
Fundació la Marató de TV3 (Barcelona, ES)
GRANT_NUMBER:

Fundació La Marató de TV3. Convocatoria 2015 Diabetes y Obesidad.
Source: Self-asserted source
Javier A. Menendez

Preclinical activity of the TKI nintedanib in combination with the flavonolignan silibinin in NSCLC tumors

2016 to 2018 | Contract
Boehringer Ingelheim España (Madrid, ES)
Source: Self-asserted source
Javier A. Menendez

FENOTIPADO DE LAS MUTACIONES NRAS EN EL CÁNCER COLORRECTAL: CARACTERIZACIÓN CLÍNICO-MOLECULAR Y BÚSQUEDA DE NUEVAS TERAPIAS

2015 to 2016 | Grant
Fundació Roses Contra el Càncer (Roses, ES)
Source: Self-asserted source
Javier A. Menendez

AJUTS DE SUPORT ALS GRUPS DE RECERCA DE CATALUNYA (SGR): GRUP CONSOLITAT DE LA GENERALITAT DE CATALUNYA (2014 SGR 00229)

2014 to 2016 | Contract
Generalitat de Catalunya (Barcelona, ES)
Source: Self-asserted source
Javier A. Menendez

Análisis del papel de las proteínas ID (Inhibitor of Differentiation) en el mecanismo de resistencia a erlotinib mediante la transición epitelio-mesénquima (EMT) en cáncer de pulmón con mutación activadora del EGFR (Epidermal Growth Factor Receptor).

2014 to 2015 | Contract
Spanish Society of Medical Oncology (SEOM) (Madrid, ES)
Source: Self-asserted source
Javier A. Menendez

CÉLULAS MADRE CON PLURIPOTENCIALIDAD INDUCIDA PARA EL MODELADO DE LA INICIACIÓN Y PROGRESIÓN TUMORAL EN MAMA

2014 to 2015 | Contract
Instituto Nacional del Cáncer de la República Argentina (Buenos Aires, AR)
Source: Self-asserted source
Javier A. Menendez

Reversing epithelial-to-mesenchymal transition (EMT)-driven resistance to crizotinib with the flavonolignan silibinin in NSCLC tumors with EML4-ALK translocation.

2014 to 2015 | Contract
Pfizer (United States) (New York, New York, US)
Source: Self-asserted source
Javier A. Menendez

Reversing epithelial-to-mesenchymal transition (EMT)-driven resistance to crizotinib with the flavonolignan silibinin in NSCLC tumors with EML4-ALK translocation

2013 to 2014 | Contract
Pfizer (NY, NY, US)
Source: Self-asserted source
Javier A. Menendez

METABOLISMO ENERGETICO Y AUTOFAGIA EN LAS CELULAS MADRE TUMORALES: BASES MOLECULARES PARA LA DEFINICION DE SUBTIPOS METABOLO-GENOMICOS INTRINSECOS DEL CANCER DE MAMA; SAF2012-38914

2012 to 2015 | Contract
Ministerio de Educación, Cultura y Deporte (España) | Ministry of Education and Science (Spain) (Madrid, ES)
GRANT_NUMBER:

PLAN NACIONAL DE I+D+I. PROYECTOS DE INVESTIGACION FUNDAMENTAL NO-ORIENTADA. Convocatoria 2012.

Source: Self-asserted source
Javier A. Menendez

ENSAYO EN FASE II, ALEATORIZADO, ABIERTO, MULTICENTRICO DE TRATAMIENTO NEOADYUVANTE CON QUIMIOTERAPIA Y TRASTUZUMAB CON O SIN LA ADICION DE METFORMINA EN MUJERES DIAGNOSTICADAS DE CANCER DE MAMA PRIMARIO HER2/ErbB2 POSITIVO; EC10-125

2010 to 2012 | Contract
DIRECCION GENERAL DE FARMACIA Y PRODUCTOS SANITARIOS (DGFPS)-Consorcio de Apoyo a la Investigación Biomédica en Red (CAIBER). (-, ES)
Source: Self-asserted source
Javier A. Menendez

PEMETREXED Y CISPLATINO EN COMBINACION CON ACIDO ZOLEDRONICO EN CANCER DE PULMON NO MICROCITICO: ESTUDIO PRECLINICO EN BUSCA DE SINERGIA ANTITUMORAL.

2010 to 2012 | Grant
FUNDACIÓ ROSES CONTRA EL CÀNCER (Roses, ES)
Source: Self-asserted source
Javier A. Menendez

ESTABLECIMIENTO DE CONDICIONES DE FABRICACION DE ACEITE DE OLIVA VIRGEN EXTRA RICO EN COMPUESTOS FENOLICOS ANTICANCERIGENOS

2009 to present | Contract
Junta de Andalucía (Sevilla, ES)
Source: Self-asserted source
Javier A. Menendez

Contratos Postdoctorales de Perfeccionamiento en Investigación en Salud “Sara Borrell”; CD08/00283

2009 to 2012 | Contract
Instituto de Salud Carlos III (-, ES)
Source: Self-asserted source
Javier A. Menendez

CETUXIMAB (ERBITUX®): BIO-FUNCTIONAL CHARACTERIZATION IN EGFR-OVEREXPRESSING TUMORS

2009 to 2011 | Contract
Merck (NJ, NJ, US)
Source: Self-asserted source
Javier A. Menendez

CORRELACION ENTRE DATOS ESPECTROMÉTRICOS Y BIOACTIVIDAD PARA LA IDENTIFICACION DE COMPUESTOS BIOACTIVOS EN EXTRACTOS VEGETALES; P09-CTS-4564

2009 to 2011 | Contract
Consejería Economía, Innovación, Ciencia y Empleo, Junta de Andalucia (-, ES)
Source: Self-asserted source
Javier A. Menendez

ESTABLECIMIENTO DE CONDICIONES DE FABRICACION DE ACEITE DE OLIVA VIRGEN EXTRA RICO EN COMPUESTOS FENOLICOS ANTICANCERIGENOS

2009 to 2011 | Contract
PROGRAMA DE INCENTIVOS para el FOMENTO de la INNOVACION, CIENCIA y EMPRESA de la JUNTA de ANDALUCIA (-, ES)
Source: Self-asserted source
Javier A. Menendez

NEO-SÍNTESIS DE ACIDOS GRASOS EN LA PATOGENESIS DEL CANCER DE MAMA. DISEÑO, CARACTERIZACION MOLECULAR Y DESARROLLO PRE-CLINICO DE FARMACOS ANTI-LIPOGENICOS CON UN MECANISMO DE ACCION ANTI-TUMORAL UNICO

2009 to 2011 | Contract
Fundación Científica Asociación Española Contra el Cáncer (-, ES)
Source: Self-asserted source
Javier A. Menendez

CETUXIMAB (ERBITUX®): BIO-FUNCTIONAL CHARACTERIZATION IN EGFR-OVEREXPRESSING TUMORS

2009 to 2010 | Contract
Merck (Germany) (Darmstadt, DE)
Source: Self-asserted source
Javier A. Menendez

DEFINICIÓN DE PERFILES PROTEÓMICOS/SECRETÓMICOS ASOCIADOS ESPECÍFICAMENTE CON LA PRESENCIA DE DISEMINACIÓN LINFÁTICA TUMORAL EN EL CÁNCER GÁSTRICO: Evaluación, validación y desarrollo de microarrays “low-cost” para definir el riesgo de diseminación linfática durante el estadiaje del cáncer gástrico en la rutina hospitalaria

2009 to 2009 | Contract
FUNDACION DE INVESTIGACION BIOMEDICA DE GIRONA DR. JOSEP TRUETA (Girona, ES)
Source: Self-asserted source
Javier A. Menendez

AJUTS DE SUPORT ALS GRUPS DE RECERCA DE CATALUNYA (SGR) GRUP CONSOLITAT DE LA GENERALITAT DE CATALUNYA SGR 00065

2008 to 2011 | Contract
Generalitat de Catalunya (-, ES)
Source: Self-asserted source
Javier A. Menendez

LC-EC/MS(IT-microTOF)-RMN PARA CARACTERIZACIÓN DE COMPUESTOS FENÓLICOS DEL ACEITE DE OLIVA VIRGEN EXTRA CON CONTRASTADA ACTIVIDAD ANTICANCERÍGENA. ESTABLECIMIENTO DE MECANISMOS DE ACCIÓN TERAPÉUTICA MEDIANTE EL ANÁLISIS DE METABOLITOS; AGR-02619

2008 to 2011 | Contract
Consejería Economía, Innovación, Ciencia y Empleo, Junta de Andalucia (-, ES)
Source: Self-asserted source
Javier A. Menendez

MOLECULAR CHARACTERIZATION and CLINICO-THERAPEUTIC DEVELOPMENT of LIPOGENIC ENZYMES in the PREVENTION and TREATMENT of BREAST CANCER; PI060778

2007 to 2010 | Contract
Instituto de Salud Carlos III (-, ES)
Source: Self-asserted source
Javier A. Menendez

RED TEMÁTICA DE INVESTIGACIÓN COOPERATIVA EN CÁNCER; RD06/0020/0028

2007 to 2010 | Contract
. (., ES)
Source: Self-asserted source
Javier A. Menendez

RED TEMÁTICA “BIOACTIVE COMPOUNDS”; AGL2007-28635-E/ALI

2007 to 2009 | Contract
Dirección General de Investigación del MINISTERIO de EDUCACIÓN y CIENCIA. PROGRAMA NACIONAL de RECURSOS y TECNOLOGÍAS AGROALIMENTARIAS (-, ES)
Source: Self-asserted source
Javier A. Menendez

MOLECULAR CHARACTERIZATION, THERAPEUTIC DEVELOPMENT and CLINICAL EVALUATION of the enzyme FATTY ACID SYNTHASE (FAS) as a METABOLIC ONCOGENE in BREAST CANCER; CP05/00090

2006 to 2009 | Contract
Instituto de Salud Carlos III (., ES)
Source: Self-asserted source
Javier A. Menendez

TARGETING FATTY ACID SYNTHASE (FAS)-DEPENDENT ENDOGENOUS FATTY ACID METABOLISM TO PREVENT BREAST CANCER: FAS AS A METABOLIC ONCOGENE IN IN SITU DUCTAL CARCINOMA OF THE BREAST; BCTR89406

2006 to 2008 | Contract
The Susan G. Komen Breast Cancer Foundation: Basic, Clinical, and Translational Cancer Research (., US)
Source: Self-asserted source
Javier A. Menendez

FATTY ACID SYNTHASE: CHARACTERIZATION AS A NOVEL MOLECULAR TARGET FOR BREAST CANCER; 5R01 CA116623-01

2005 to 2008 | Contract
National Institutes of Health (MD, MD, US)
GRANT_NUMBER:

R01 Grants
Source: Self-asserted source
Javier A. Menendez

EFFECTS of DIETARY FATTY ACIDS in Her-2/neu (erbB-2) ONCOGENE-INDUCED BREAST CANCER TUMORIGENESIS and TRASTUZUMAB (HERCEPTIN™) EFFICACY

2005 to 2006 | Contract
Evanston Northwestern Healthcare Breast Program (Evanston , US)
GRANT_NUMBER:

Concept/Pilot Award Program
Source: Self-asserted source
Javier A. Menendez

MOLECULAR MECHANISMS and THERAPEUTIC IMPLICATIONS of a NOVEL BI-DIRECTIONAL CROSS-TALK between the LIPOGENIC ENZYME FATTY ACID SYNTHASE (FAS) and the HER-2/neu ONCOGENE in BREAST CANCER; BCTR0403141

2004 to 2006 | Contract
The Susan G. Komen Breast Cancer Foundation: Basic, Clinical, and Translational Cancer Research (., US)
Source: Self-asserted source
Javier A. Menendez

CHARACTERIZATION OF FATTY ACID SYNTHASE (FAS) AS A PREDICTIVE MARKER OF BREAST CANCER SENSITIVITY TO CHEMOTHERAPY; BC033538

2004 to 2005 | Contract
U.S. Department of Defense (DC, DC, US)
GRANT_NUMBER:

Breast Cancer Research Program –BCRP-: Concept Awards
Source: Self-asserted source
Javier A. Menendez

FATTY ACID SYNTHASE (FAS) AND BREAST CANCER SENSITIVITY TO CHEMOTHERAPY AND ENDOCRINE THERAPIES

2004 to 2005 | Contract
National Cancer Institute (MD, MD, US)
GRANT_NUMBER:

Specialized Program of Research Excellence –SPORE- in Breast Cancer, National Cancer Institute –NCI-: CAREER DEVELOPMENT AWARD
Source: Self-asserted source
Javier A. Menendez

MOLECULAR TARGETING OF TUMOR-ASSOCIATED FATTY ACID SYNTHASE: A NOVEL THERAPEUTIC APPROACH AGAINST HER-2/NEU-OVEREXPRESSING BREAST CARCINOMAS; PP2

2003 to 2004 | Contract
National Cancer Institute (MD, MD, US)
GRANT_NUMBER:

Specialized Program of Research Excellence –SPORE- in Breast Cancer, National Cancer Institute –NCI-: Pilot Projects Program
Source: Self-asserted source
Javier A. Menendez

PHARMACOLOGICAL INHIBITION OF FATTY ACID SYNTHASE: A NEW THERAPEUTIC APPROACH in Her-2/neu-OVEREXPRESSING BREAST CANCER

2003 to 2004 | Contract
Evanston Northwestern (Evanston, US)
GRANT_NUMBER:

Evanston Northwestern Healthcare Breast Program: Concept/Pilot Award Program
Source: Self-asserted source
Javier A. Menendez

EXPERIMENTAL EVALUATION OF DIETARY FATTY ACIDS AS A THERAPEUTIC STRATEGY IN BREAST CANCER

2001 to 2004 | Contract
Instituto Danone (Barcelona, ES)
Source: Self-asserted source
Javier A. Menendez

ROLE OF HEREGULIN IN BREAST CANCER NEOVASCULARIZATION; DAMD17-001-0305

2001 to 2004 | Contract
U.S. Department of Defense (DC, DC, US)
GRANT_NUMBER:

Department of Defense, Breast Cancer Research Program –BCRP
Source: Self-asserted source
Javier A. Menendez

OMEGA-3 FATTY ACIDS IN THE PROGRESSION OF BREAST CANCER

1999 to 2000 | Contract
Sociedad Española de Oncología Médica (., ES)
Source: Self-asserted source
Javier A. Menendez

CLINICAL IMPLICATIONS OF OMEGA-3 FATTY ACIDS IN BREAST CANCER PROGRESSION

1997 to 2001 | Contract
Comunidad Autónoma de Madrid (Madrid, ES)
Source: Self-asserted source
Javier A. Menendez

EXPERIMENTAL EVALUATION OF OLIVE OIL IN THE PREVENTION OF BREAST CANCER METASTASIS; OLI96/2114

1997 to 2000 | Contract
MINISTERIO DE EDUCACION Y CULTURA (Madrid, ES)
GRANT_NUMBER:

PLAN NACIONAL DE I+D+I. PROYECTOS DE INVESTIGACION FUNDAMENTAL NO-ORIENTADA 1997
Source: Self-asserted source
Javier A. Menendez

FATTY ACIDS MODULATION OF ANGIOGENIC FACTORS AND ONCOGENES EXPRESSION; FIS 96/0226

1997 to 1998 | Contract
Instituto de Salud Carlos III (., ES)
Source: Self-asserted source
Javier A. Menendez

ENERGY METABOLISM, AUTOPHAGY and BREAST CANCER GENETIC INSTABILITY: MOLECULAR DYNAMICS and THERAPEUTIC OPPORTUNITIES; SAF2009-11579

Contract
Ministerio de Ciencia e Innovación (-, ES)
GRANT_NUMBER:

PLAN NACIONAL DE I+D+I (2008-2011). PROYECTOS DE INVESTIGACION FUNDAMENTAL NO-ORIENTADA
Source: Self-asserted source
Javier A. Menendez
How many people are using ORCID?